Hospital Acquired Disease Testing Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the global hospital acquired disease testing market looks promising with opportunities in hospitals and intensive care units (ICUS). The global hospital acquired disease testing market is expected to grow with a CAGR of 14%-16% from 2020 to 2025. The major drivers for this market are increasing prevalence of hospital acquired infections, growing number of drug-resistant pathogens, and rising awareness among people of hospital acquired diseases.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global hospital acquired disease testing market report, please download the report brochure.
In this market, urinary tract infection is the fastest growing test type of hospital acquired disease testing, whereas hospitals and intensive care units (ICUs) is the fastest growing end user. Growth in various segments of the hospital acquired disease testing market are given below:
The study includes trends and forecast for the global hospital acquired disease testing market by test type, end user, and region as follows:
By Test Type [Value ($ Million) shipment analysis for 2014 – 2025]:
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-Resistant Staphylococcus Aureus
By End User [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospitals and Intensive Care Units (ICUs)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes and Maternity Centers
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
Spain
Italy
France
Asia Pacific
China
Japan
India
The Rest of the World
Brazil
Some of the hospital acquired disease testing companies profiled in this report include Diatherix Corp, Roche, Cantel Medical Corporation, Qiagen, and Cephid, bioMeriux.
Lucintel forecasts that urinary tract infection will remain the largest test type segment over the forecast period due to high prevalence of hospital acquired infections and increasingly popular techniques that are being used for preventing, diagnosing, & treating the hospital-associated infections, such as polymerise chain reaction (PCR), solid-phase hybridization, and microarrays.
Within this market, hospitals and intensive care units (ICUs) will remain the largest end user segment over the forecast period.
North America will remain the largest region over the forecast period due to increase in geriatric population and robust healthcare infrastructure in this region.
Features of the Global Hospital Acquired Disease Testing Market
Market Size Estimates: Global hospital acquired disease testing market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Global hospital acquired disease testing market size by various segments, such as test type and end user in terms of value.Regional Analysis: Global hospital acquired disease testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.Growth Opportunities: Analysis of growth opportunities in different test type, ens user, and region for the global hospital acquired disease testing market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global hospital acquired disease testing market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the global hospital acquired disease testing market by test type (urinary tract infection, surgical site infection, pneumonia stents, blood stream infection, and methicillin-resistant staphylococcus aureus), end user (hospitals and intensive care units (ICUs), ambulatory surgical and diagnostic centers, and nursing homes and maternity centers), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global hospital acquired disease testing market?
Q.5 What are the business risks and threats to the global hospital acquired disease testing market?
Q.6 What are the emerging trends in this hospital acquired disease testing market and the reasons behind them?
Q.7 What are some changing demands of customers in this hospital acquired disease testing market?
Q.8 What are the new developments in this hospital acquired disease testing market? Which companies are leading these developments?
Q.9 Who are the major players in this hospital acquired disease testing market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this hospital acquired disease testing market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global hospital acquired disease testing market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus), and End User (Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers)
Regional Scope North America (USA, Mexico, and Canada), Europe (Germany, United Kingdom, Spain, Italy, and France), Asia (China, Japan, and India), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the global hospital acquired disease testing market looks promising with opportunities in hospitals and intensive care units (ICUS). The global hospital acquired disease testing market is expected to grow with a CAGR of 14%-16% from 2020 to 2025. The major drivers for this market are increasing prevalence of hospital acquired infections, growing number of drug-resistant pathogens, and rising awareness among people of hospital acquired diseases.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global hospital acquired disease testing market report, please download the report brochure.
In this market, urinary tract infection is the fastest growing test type of hospital acquired disease testing, whereas hospitals and intensive care units (ICUs) is the fastest growing end user. Growth in various segments of the hospital acquired disease testing market are given below:
The study includes trends and forecast for the global hospital acquired disease testing market by test type, end user, and region as follows:
By Test Type [Value ($ Million) shipment analysis for 2014 – 2025]:
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-Resistant Staphylococcus Aureus
By End User [Value ($ Million) shipment analysis for 2014 – 2025]:
Hospitals and Intensive Care Units (ICUs)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes and Maternity Centers
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
Spain
Italy
France
Asia Pacific
China
Japan
India
The Rest of the World
Brazil
Some of the hospital acquired disease testing companies profiled in this report include Diatherix Corp, Roche, Cantel Medical Corporation, Qiagen, and Cephid, bioMeriux.
Lucintel forecasts that urinary tract infection will remain the largest test type segment over the forecast period due to high prevalence of hospital acquired infections and increasingly popular techniques that are being used for preventing, diagnosing, & treating the hospital-associated infections, such as polymerise chain reaction (PCR), solid-phase hybridization, and microarrays.
Within this market, hospitals and intensive care units (ICUs) will remain the largest end user segment over the forecast period.
North America will remain the largest region over the forecast period due to increase in geriatric population and robust healthcare infrastructure in this region.
Features of the Global Hospital Acquired Disease Testing Market
Market Size Estimates: Global hospital acquired disease testing market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Global hospital acquired disease testing market size by various segments, such as test type and end user in terms of value.Regional Analysis: Global hospital acquired disease testing market breakdown by North America, Europe, Asia Pacific, and Rest of the World.Growth Opportunities: Analysis of growth opportunities in different test type, ens user, and region for the global hospital acquired disease testing market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global hospital acquired disease testing market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the global hospital acquired disease testing market by test type (urinary tract infection, surgical site infection, pneumonia stents, blood stream infection, and methicillin-resistant staphylococcus aureus), end user (hospitals and intensive care units (ICUs), ambulatory surgical and diagnostic centers, and nursing homes and maternity centers), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global hospital acquired disease testing market?
Q.5 What are the business risks and threats to the global hospital acquired disease testing market?
Q.6 What are the emerging trends in this hospital acquired disease testing market and the reasons behind them?
Q.7 What are some changing demands of customers in this hospital acquired disease testing market?
Q.8 What are the new developments in this hospital acquired disease testing market? Which companies are leading these developments?
Q.9 Who are the major players in this hospital acquired disease testing market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this hospital acquired disease testing market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global hospital acquired disease testing market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus), and End User (Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers)
Regional Scope North America (USA, Mexico, and Canada), Europe (Germany, United Kingdom, Spain, Italy, and France), Asia (China, Japan, and India), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Hospital Acquired Disease Testing Market Trends and Forecast
3.3: Global Hospital Acquired Disease Testing Market by Test Type
3.3.1: Urinary Tract Infection
3.3.2: Surgical Site Infection
3.3.3: Pneumonia Stents
3.3.4: Blood Stream Infection
3.3.5: Methicillin-Resistant Staphylococcus Aureus
3.4: Global Hospital Acquired Disease Testing Market by End User
3.4.1: Hospitals and Intensive Care Units (ICUs)
3.4.2: Ambulatory Surgical and Diagnostic Centers
3.4.3: Nursing Homes and Maternity Centers
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Hospital Acquired Disease Testing Market by Region
4.2: North American Hospital Acquired Disease Testing Market
4.2.1: Market by Test Type: Urinary Tract Infection, Surgical Site Infection,Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus
4.2.2: Market by End User: Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers
4.2.3: The United States Hospital Acquired Disease Testing Market
4.2.4: The Canadian Hospital Acquired Disease Testing Market
4.2.5: The Mexican Hospital Acquired Disease Testing Market
4.3: European Hospital Acquired Disease Testing Market
4.3.1: Market by Test Type: Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus
4.3.2: Market by End User: Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers
4.3.3: The German Hospital Acquired Disease Testing Market
4.3.4: The United Kingdom Hospital Acquired Disease Testing Market
4.3.5: The Spain Hospital Acquired Disease Testing Market
4.3.6: The Italy Hospital Acquired Disease Testing Market
4.3.7: The French Hospital Acquired Disease Testing Market
4.4: APAC Hospital Acquired Disease Testing Market
4.4.1: Market by Test Type: Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus
4.4.2: Market by End User: Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers
4.4.3: The Chinese Hospital Acquired Disease Testing Market
4.4.4: The Indian Hospital Acquired Disease Testing Market
4.4.5: The Japanese Hospital Acquired Disease Testing Market
4.5: ROW Hospital Acquired Disease Testing Market
4.5.1: Market by Test Type: Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus
4.5.2: Market by End User: Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers
4.5.3: Brazilian Hospital Acquired Disease Testing Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Hospital Acquired Disease Testing Market by Test Type
7.1.2: Growth Opportunities for the Global Hospital Acquired Disease Testing Market by End User
7.1.3: Growth Opportunities for the Global Hospital Acquired Disease Testing Market by Region
7.2: Emerging Trends in the Global Hospital Acquired Disease Testing Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Hospital Acquired Disease Testing Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Hospital Acquired Disease Testing Market
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Diatherix Corp
8.2: Roche
8.3: Cantel Medical Corporation
8.4: Qiagen
8.5: Cephid
8.6: Company
8.7: Company
8.8: Company
8.9: Company
8.10: Company
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Hospital Acquired Disease Testing Market Trends and Forecast
3.3: Global Hospital Acquired Disease Testing Market by Test Type
3.3.1: Urinary Tract Infection
3.3.2: Surgical Site Infection
3.3.3: Pneumonia Stents
3.3.4: Blood Stream Infection
3.3.5: Methicillin-Resistant Staphylococcus Aureus
3.4: Global Hospital Acquired Disease Testing Market by End User
3.4.1: Hospitals and Intensive Care Units (ICUs)
3.4.2: Ambulatory Surgical and Diagnostic Centers
3.4.3: Nursing Homes and Maternity Centers
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Hospital Acquired Disease Testing Market by Region
4.2: North American Hospital Acquired Disease Testing Market
4.2.1: Market by Test Type: Urinary Tract Infection, Surgical Site Infection,Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus
4.2.2: Market by End User: Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers
4.2.3: The United States Hospital Acquired Disease Testing Market
4.2.4: The Canadian Hospital Acquired Disease Testing Market
4.2.5: The Mexican Hospital Acquired Disease Testing Market
4.3: European Hospital Acquired Disease Testing Market
4.3.1: Market by Test Type: Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus
4.3.2: Market by End User: Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers
4.3.3: The German Hospital Acquired Disease Testing Market
4.3.4: The United Kingdom Hospital Acquired Disease Testing Market
4.3.5: The Spain Hospital Acquired Disease Testing Market
4.3.6: The Italy Hospital Acquired Disease Testing Market
4.3.7: The French Hospital Acquired Disease Testing Market
4.4: APAC Hospital Acquired Disease Testing Market
4.4.1: Market by Test Type: Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus
4.4.2: Market by End User: Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers
4.4.3: The Chinese Hospital Acquired Disease Testing Market
4.4.4: The Indian Hospital Acquired Disease Testing Market
4.4.5: The Japanese Hospital Acquired Disease Testing Market
4.5: ROW Hospital Acquired Disease Testing Market
4.5.1: Market by Test Type: Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, and Methicillin-Resistant Staphylococcus Aureus
4.5.2: Market by End User: Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, and Nursing Homes and Maternity Centers
4.5.3: Brazilian Hospital Acquired Disease Testing Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Hospital Acquired Disease Testing Market by Test Type
7.1.2: Growth Opportunities for the Global Hospital Acquired Disease Testing Market by End User
7.1.3: Growth Opportunities for the Global Hospital Acquired Disease Testing Market by Region
7.2: Emerging Trends in the Global Hospital Acquired Disease Testing Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Hospital Acquired Disease Testing Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Hospital Acquired Disease Testing Market
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Diatherix Corp
8.2: Roche
8.3: Cantel Medical Corporation
8.4: Qiagen
8.5: Cephid
8.6: Company
8.7: Company
8.8: Company
8.9: Company
8.10: Company
